Previse, formerly known as Capsulomics Inc., raised $3 million in seed financing to support the launch of its first laboratory-developed test (LDT), Esopredict. The precision medicine test is designed to detect Barrett’s esophagus (BE) and predict which BE patients will progress to esophageal cancer.

Startup Aiomic ApS received a capital injection in the form of a €1.3 million (US$1.4 million) convertible loan from Denmark’s Bioinnovation Institute (BII) that will allow the company to further develop and commercialize its artificial intelligence (AI)-driven Aiomic360 platform, which is designed to reduce the number of postoperative complications.

Yongrenxin Medical Instrument Co. Ltd. raised nearly $100 million in a series A funding round to build a health platform to treat heart failures. Sinovac Biotech Ltd. led the round.

Mvision AI Oy raised €5.4 million (US$5.8 million) in a post seed funding round to help accelerate the development of its artificial intelligence (AI)-powered automatic segmentation software, which automates and standardizes radiotherapy treatment for patients. Mvision aims to make same day cancer treatment a standard globally. The funding was led by J12 Ventures and Voima Ventures.

Flare Therapeutics Inc. has announced a US$123 million series B financing to support its work targeting novel transcription factors for cancer and other diseases.

Vitestro Holding BV reported raising $12.7 million in series A financing round to develop the world’s first autonomous blood drawing device. This round was led by Sonder Capital Inc., alongside existing investors and new angel investors with experience in the clinical laboratory and med-tech industry. “Thanks to this fundraising, we are going to accelerate the product development, prepare EU marketing authorization, and initiate production,” Toon Overbeeke, CEO and co-founder of Vitestro, explains to BioWorld.